Sanofi snares Novartis' Nathwani

Amy Schofield 14 March 2016

Sanofi has appointed Dr Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer.

Dr Nathwani joins Sanofi from Novartis and will take the position of Executive Vice President, Group Chief Medical Officer. The appointment is effective as of May 1, 2016. 

Dr. Nathwani has over 20 years of experience in the pharmaceutical industry. He joined Glaxo Group Research in 1994, then from 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and has held a number of senior development and commercial positions in the company. 

In cooperation with Global R&D and the Global Business Units, Dr Nathwani is tasked with ensuring the highest standards of transparency and compliance in Sanofi's interactions with healthcare providers, patients and medical organisations.

Olivier Brandicourt, Chief Executive Officer of Sanofi, said: "We are very happy to count on Ameet's strong experience in both development and medical fields."

Dr Nathwani succeeds Dr Paul Chew who has served as Senior Vice President, Chief Medical Officer since January 2013. Dr Chew is planning to retire later this year.


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.